Roche - ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
Links shared publicly online about this topic.
- 793total visits
Roche - ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
Roche - ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
View full resource at roche.com
Tags: Arthritis, Rheumatoid Arthritis Medication, Juvenile Rheumatoid Arthritis, Children's Health, Actemra
Most Recently Shared on October 18, 2010 at 7:22 am By:
ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe http://bit.ly/d07HsG #RocheIR
Advertisement
